We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

172 hedge funds and large institutions have $835M invested in UroGen Pharma in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

11% more call options, than puts

Call options by funds: $4.26M | Put options by funds: $3.83M

11% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 47

3% more funds holding

Funds holding: 167 → 172 (+5)

1.97% more ownership

Funds ownership: 93.38% → 95.36% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

18% less capital invested

Capital invested by funds: $1.02B → $835M (-$189M)

Holders
172
Holders Change
+5
Holders Change %
+2.99%
% of All Funds
2.12%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
33
Increased
52
Reduced
47
Closed
25
Calls
$4.26M
Puts
$3.83M
Net Calls
+$423K
Net Calls Change
-$26.3M

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$52.5M
2
KCM
Kynam Capital Management
New Jersey
+$45.1M
3
OM
Opaleye Management
Massachusetts
+$23.3M
4
SCM
Soleus Capital Management
Connecticut
+$11.6M
5
FCM
Frontier Capital Management
Massachusetts
+$10.7M

Top Sellers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
-$55.5M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$14.8M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.8M
4
Citadel Advisors
Citadel Advisors
Florida
-$9.42M
5
SCM
Superstring Capital Management
New York
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
51
ARK Investment Management
Florida
$2.08M -$119K -5,939 -5%
ACM
52
Aisling Capital Management
New York
$1.94M – – –
TI
53
Tidal Investments
Wisconsin
$1.85M +$1.52M +75,977 +282%
Wellington Management Group
54
Wellington Management Group
Massachusetts
$1.8M -$518K -25,819 -20%
Bank of New York Mellon
55
Bank of New York Mellon
New York
$1.78M +$2.27K +113 +0.1%
PAM
56
Panagora Asset Management
Massachusetts
$1.76M +$481K +24,000 +32%
Charles Schwab
57
Charles Schwab
California
$1.59M -$50.6K -2,523 -3%
N
58
Nuveen
North Carolina
$1.57M -$4.31M -215,079 -71%
ORI
59
Oak Ridge Investments
Illinois
$1.55M +$23.5K +1,173 +1%
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$1.5M -$1.59M -79,102 -49%
Swiss National Bank
61
Swiss National Bank
Switzerland
$1.4M +$1.56M +77,800 New
TI
62
Trexquant Investment
Connecticut
$1.33M +$1.48M +73,905 New
Truist Financial
63
Truist Financial
North Carolina
$1.3M – – –
ECM
64
ExodusPoint Capital Management
New York
$1.26M +$699K +34,847 +98%
Russell Investments Group
65
Russell Investments Group
United Kingdom
$1.14M +$321K +15,989 +34%
AC
66
Annandale Capital
Texas
$1.05M -$40.1K -2,000 -3%
Wells Fargo
67
Wells Fargo
California
$1M -$569K -28,401 -34%
RhumbLine Advisers
68
RhumbLine Advisers
Massachusetts
$888K +$73.1K +3,647 +8%
HF
69
HRT Financial
New York
$887K -$1.63M -81,536 -62%
UBS AM
70
UBS AM
Illinois
$853K +$943K +47,016 +11,667%
AllianceBernstein
71
AllianceBernstein
Tennessee
$821K – – –
VOYA Investment Management
72
VOYA Investment Management
Georgia
$782K -$667K -33,264 -43%
California State Teachers Retirement System (CalSTRS)
73
California State Teachers Retirement System (CalSTRS)
California
$697K +$731K +36,478 +1,606%
CBA
74
Coastal Bridge Advisors
Connecticut
$665K – – –
BRA
75
Bender Robert & Associates
California
$624K +$696K +34,701 New
1 2
3
4 5

URGN Hedge Fund Activity: Q1 2026 in Review

172 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2026, worth a combined $835M — down 18% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new URGN positions and 25 closed out — a net gain of 8 holders — while 52 added to existing stakes and 47 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $52.5M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $55.5M.

  • 172 institutional investors held UroGen Pharma (URGN) as of Q1 2026, up from 167 in Q4 2025.
  • Funds reported $835M of UroGen Pharma stock for Q1 2026, down 18% quarter-over-quarter.
  • 33 funds opened new UroGen Pharma positions in Q1 2026 and 25 closed out, a net change of +8 holders.
  • The largest UroGen Pharma buyer in Q1 2026 was Toronto Dominion Bank, an estimated $52.5M added.
  • The largest UroGen Pharma seller in Q1 2026 was Paradigm Biocapital Advisors, an estimated $55.5M sold.

Based on aggregated 13F filings for Q1 2026.